Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol May Have Grounds For Fraud Case Against Apotex – Attorney

This article was originally published in The Pink Sheet Daily

Executive Summary

Wiley Rein & Fielding partner says Bristol-Myers Squibb may have a case against Apotex for sabotaging the Plavix settlement deal.

You may also be interested in...



Plavix Sales Plummet With Generic Entry

Bristol estimates that “at risk” launch of generic clopidogrel impacted U.S. pharma sales by $525 mil. to $600 mil.

Plavix Sales Plummet With Generic Entry

Bristol estimates that “at risk” launch of generic clopidogrel impacted U.S. pharma sales by $525 mil. to $600 mil.

Apotex Appeal On Plavix Preliminary Injunction Ruling To Begin Oct. 31

Appeals court denies Apotex' motion to stay a preliminary injunction blocking sales of generic clopidogrel.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063197

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel